๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Differentiation therapy in acute promyelocytic leukemia: European experience

โœ Scribed by Laurent Degos

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
80 KB
Volume
173
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

โœฆ Synopsis

Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia characterized by the morphology of the blast cells (M3 type in the FAB nomenclature), and a specific t(15;17) translocation. APL was further characterized by a specific sensitivity to all-trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARa and a gene called PML. In vivo differentiation therapy with retinoids in APL patients reduces the risk of relapse and increases the chance of long-term survival.

๐Ÿ“œ SIMILAR VOLUMES

Prophylactic heparin therapy in acute pr
Prophylactic heparin therapy in acute promyelocytic leukemia
โœ Robert L. Drapkin; Timothy S. Gee; Monroe D. Dowling; Zalmen Arlin; Susan McKenz ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 424 KB ๐Ÿ‘ 1 views

Twenty-four patients with acute promyelocytic leukemia were reviewed. Group I, treated between July 1970 and September 1973, received arabinosylcytosine and 6-thioguanine, and there was one complete remission, with 4 7 dying during induction with intracerebral hemorrhages, and 217 dying within one m

Successful pregnancy in acute promyelocy
Successful pregnancy in acute promyelocytic leukemia
โœ A. Alegre; R. Chunchurreta; J. Rodriguez-Alarcon; E. Cruz; M. Prada ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 1 views
Morphologic heterogeneity of acute promy
Morphologic heterogeneity of acute promyelocytic leukemia: Therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology
โœ S. Sinha; L. Aish; T.H. Oo ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 285 KB

To the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML. The prognosis of Ph รพ AML is very poor with a median survival time of only 7 months. We present two patients with de novo Ph รพ AML who received induction chemotherapy and post-remission imati